nct_id: NCT05872867
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2023-05-24'
study_start_date: null
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Biological: Pembrolizumab'
  - drug_name: 'Biological: WM-A1-3389'
long_title: An Open-label, Dose-escalation, Phase 1 Study to Investigate the Safety
  and Tolerability of WM-A1-3389, in Combination With Pembrolizumab in Patients With
  Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer
last_updated: '2024-03-12'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE1
principal_investigator: NA
principal_investigator_institution: Wellmarker Bio
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 54
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'Inclusion Criteria:'
- '\[Stage 1: monotherapy\]'
- "1. Be \u226519 and \\<75 years of age"
- 2. Participant with histologically and/or cytologically confirmed diagnosis of unresectable
  advanced or metastatic solid tumors that have been confirmed as progressed disease
  after standard of care or for which no further standard therapy is available due
  to intolerance or incompatibility
- 3. IGSF1 positive expression
- 4. Have measurable disease defined as at least one lesion based on Response Evaluation
  Criteria In Solid Tumors (RECIST) v1.1
- 5. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
  1
- "6. Have life expectancy \u2265 12 weeks"
- '7. Have adequate organ functions defined as the following laboratory test criteria
  at screening (During the screening phase, one re-test will be permitted):'
- "1. Absolute neutrophil count (ANC) \u2265 1,500/mm3"
- "2. Platelet count \u2265 100,000/mm3"
- "3. Hemoglobin (Hb) \u2265 9 g/dL"
- "4. Total bilirubin \u2264 1.5 X Institutional Upper Limit of Normal (IULN) (Not\
  \ applicable to patients with Gilbert syndrome)"
- "5. Serum creatinine \u2264 1.5 X IULN"
- "6. Aspartate aminotransferase (AST) and/or Alanine aminotransferase (ALT) \u2264\
  \ 2.5 X IULN (AST and ALT \u2264 5 X IULN in patients with confirmed liver metastasis)"
- "7. Prothrombin time (PT) \u2264 1.5 X IULN \\*IULN: Institutional Upper Limit of\
  \ Normal"
- 8. Have provided archival tumor tissue sample obtained within 3 months prior to
  IP administration or newly obtained biopsy
- 9. Have agreed to undergo up to 2 tumor tissue biopsies after IP administration
- 10. Participant (or legally acceptable representative if applicable) provides written
  informed consent for the trial
- '\[Stage 2: Combination therapy\]'
- "1. Be \u2265 19 and \\< 75 years of age"
- 2. Participant with histologically and/or cytologically confirmed diagnosis of unresectable
  advanced or metastatic NSCLC
- 1. Have been confirmed as progressive disease after standard of care or for which
  no further standard therapy is available due to intolerance or incompatibility
- 2. Have been confirmed as progressive disease during or after anti-cancer therapy
  including programmed cell death protein 1 (PD-1) inhibitors and programmed cell
  death-Ligand 1 (PD-L1) inhibitors
- 3. IGSF1 positive expression
- 4. PD-L1 low or negative expression (tumor proportion score \[TPS\] \< 50%)
- 3. Have measurable disease defined as at least one lesion based on Response Evaluation
  Criteria In Solid Tumors (RECIST) v1.1
- 4. Have ECOG performance status score of 0 or 1
- "5. Have life expectancy \u2265 12 weeks"
- '6. Have adequate organ functions defined as the following laboratory test criteria
  at screening (During the screening period, one re-test will be permitted):'
- "1. Absolute neutrophil count (ANC) \u2265 1500/mm3"
- "2. Platelet count \u2265 100,000/mm3"
- "3. Hemoglobin (Hb) \u2265 9 g/dL"
- "4. Total bilirubin \u2264 1.5 X IULN (Not applicable to patients with Gilbert's\
  \ syndrome)"
- "5. Serum creatinine \u2264 1.5 X IULN"
- "6. Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) \u2264 2.5\
  \ X IULN (AST and ALT \u2264 5 X IULN in patients with confirmed liver metastasis)"
- "7. Prothrombin time (PT) \u2264 1.5 X IULN \\*IULN: Institutional Upper Limit of\
  \ Normal"
- 7. Have provided archival tumor sample obtained within 3 months prior to IP administration
  or newly obtained biopsy prior to IP administration
- 8. Have agreed to undergo up to 2 tumor tissue biopsies after IP administration
- 9. Participant (or legally acceptable representative if applicable) provides written
  infromed consent for the trial
- 'Exclude - Exclusion Criteria:'
- Exclude - \[Common\]
- Exclude - 1. Have experienced hypersensitivity to IP, any of its excipients or other
  monoclonal antibody
- 'Exclude - 2. Have any of the following documented medical history or surgical/procedure
  history:'
- Exclude - 1. Other primary malignant tumor (subject may be enrolled if they have
  neither received any treatment nor experienced disease progression within 3 years)
  or hematologic malignancy
- Exclude - 2. Major surgery within 4 weeks or minor surgery within 2 weeks prior
  to IP administration
- "Exclude - 3. Clinically significant arrhythmia, acute myocardial infarction, unstable\
  \ angina pectoris, or New York Heart Association (NYHA) class \u2162 or \u2163 heart\
  \ failure within 6 months prior to IP administration"
- Exclude - 4. Severe cerebrovascular disease within 6 months prior to IP administration
- Exclude - 5. Pulmonary thrombosis, deep vein thrombosis, bronchial asthma, obstructive
  pulmonary disease, or other severe or life-threatening lung diseases (e.g., acute
  respiratory distress syndrome, lung failure) considered to be inappropriate for
  study participationt, within 6 months prior to IP administration
- Exclude - 6. Pneumonia or interstitial lung disease requiring steroids
- "Exclude - f. Infection requiring systemic antibiotics or antiviral agents, etc.\
  \ or uncontorlled Grade \u2265 3 active infectious diseases within 2 weeks prior\
  \ to IP administration g. Risk factors of ileus or intestinal perforation (including\
  \ but not limited to history of acute diverticulitis, intra-abdominal abscess, and\
  \ abdominal carcinomatosis) h. Auto-immune diseases"
- 'Exclude - 3. Have any of the following diseases:'
- Exclude - 1. Central nervous system or brain metastasis that is uncontrolled or
  with clinically significant symptoms (except for patients who stopped systemic corticosteroids
  at least 4 weeks before IP administration and have been stable for at least 4 weeks)
- Exclude - 2. Abnormal ECG regarded as clinically significant by the investigator
- Exclude - 3. Uncontrolled hypertension (systolic blood pressure \[SBP\] \> 160 mmHg
  or diastolic blood pressure \[DBP\] \> 100 mmHg)
- Exclude - 4. Active infection requiring treatment
- Exclude - 5. Active hepatitis B or C virus infection
- Exclude - 6. History of human immunodeficiency virus infection (HIV) infection
- Exclude - 7. Symptomatic ascites or pleural effusion (except for patients who were
  treated and clinically stable)
- Exclude - 8. Diseases that may affect the study results based on the judgement of
  the investigator
- 'Exclude - 4. Have any of the following medication or treatment history:'
- Exclude - 1. Anticancer therapy (chemotherapy, hormonal therapy, targeted therapy,
  or radiotherapy) within 4 weeks prior to IP administration
- Exclude - 2. Immunotherapy such as anti-PD-1, anti PD-L1, anti-cytotoxic T-lymphocyte-associated
  protein 4 (CTLA-4), etc. within 4 weeks prior to IP administration
- Exclude - 3. Treatment with live attenuated vaccine within 4 weeks prior to IP administration
- "Exclude - 4. Treatment with drugs classified as Immunosuppressants, immunomodulators,\
  \ or immunocytokines within 1 week prior to IP administration (Immunosuppressants,\
  \ topical corticosteroids, prednisolone 10 mg/day or \u2264 equivalent dose of systemic\
  \ corticosteroids may be permitted for the treatment or prevention of AEs.)"
- Exclude - 5. Allogeneic bone marrow or solid organ transplantation
- Exclude - 5. Pregnant women, lactating women or men/women of child-bearing potential
  who are unwilling to maintain abstinence or use adequate methods of contraception
  or do not consent to refrain from donation of sperm/ova for at least 6 months after
  the last IP administration
- Exclude - \* Adequate methods of contraception
- Exclude - 1. Oral or injectable hormonal therapy
- Exclude - 2. Implantation of intrauterine device or intrauterine system
- Exclude - 3. Surgical sterilization (vasectomy, tubal ligation, etc.)
- Exclude - 6. Have received any other IP or implantation of investigational medical
  device within 4 weeks prior to IP administration in the present study
- Exclude - 7. Patients who are considered ineligible or unable to participate in
  the study for other reasons based on the judgement of the investigator
short_title: Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid
  Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90)
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: Wellmarker Bio
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: The purpose of the present study is to determine the safety, tolerability,
  and efficacy of WM-A1-3389 in combination with pembrolizumab in participants with
  advanced or metastatic solid tumors and non-small cell lung cancer (NSCLC).
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: Dose escalation (Stage 1)
      arm_internal_id: 0
      arm_description: WM-A1-3389 administered intravenously, weekly for 21 days of
        each cycle
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Biological: WM-A1-3389'
        level_internal_id: 0
        level_suspended: N
    - arm_code: Dose escalation (Stage 2)
      arm_internal_id: 1
      arm_description: WM-A1-3389 administered intravenously, weekly for 21 days of
        each cycle Pembrolizumab 200 mg administered intravenously, every 3 weeks
        for 21 days of each cycle
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Biological: WM-A1-3389'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Biological: Pembrolizumab'
        level_internal_id: 1
        level_suspended: N
    match:
    - clinical:
        age_numerical: '>=19'
        pdl1_status: Low
        disease_status:
        - Advanced
        - Metastatic
        oncotree_primary_diagnosis: _SOLID_
